Literature DB >> 22391776

Surgical management of proximal bile duct cancers.

Jennifer LaFemina1, William R Jarnagin.   

Abstract

INTRODUCTION: Tumors arising from the proximal biliary tree remain particularly challenging with respect to their evaluation and treatment. Complete resection with negative histologic margins is the most effective treatment modality.
RESULTS: However, the majority of patients are not candidates for surgery. Over the last decades, advances have evolved to improve resectability and morbidity after major liver and bile duct resection. However, these disease processes still pose a management challenge. Herein, we provide an overview of proximal bile duct cancers, hilar cholangiocarcinoma (HCCa) and intrahepatic cholangiocarcinoma (ICCa).

Entities:  

Mesh:

Year:  2012        PMID: 22391776     DOI: 10.1007/s00423-012-0928-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  99 in total

1.  A western surgical experience of peripheral cholangiocarcinoma.

Authors:  S V Berdah; J R Delpero; S Garcia; J Hardwigsen; Y P Le Treut
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures.

Authors:  M Rabinovitz; A B Zajko; T Hassanein; B Shetty; K M Bron; R R Schade; J S Gavaler; G Block; D H Van Thiel; A Dekker
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

Review 4.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

5.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 6.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

7.  Role of liver atrophy, hepatic resection and hepatocyte hyperplasia in the development of portal hypertension in biliary disease.

Authors:  N S Hadjis; L H Blumgart
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

8.  Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.

Authors:  A Nakeeb; P A Lipsett; K D Lillemoe; M K Fox-Talbot; J Coleman; J L Cameron; H A Pitt
Journal:  Am J Surg       Date:  1996-01       Impact factor: 2.565

9.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

Review 10.  Unresectable malignant biliary obstruction: treatment by self-expandable biliary endoprostheses.

Authors:  A Glättli; S C Stain; H U Baer; W Schweizer; J Triller; L H Blumgart
Journal:  HPB Surg       Date:  1993
View more
  10 in total

1.  Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.

Authors:  Traian Dumitrascu; Dragos Chirita; Mihnea Ionescu; Irinel Popescu
Journal:  J Gastrointest Surg       Date:  2013-01-15       Impact factor: 3.452

Review 2.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

Review 3.  Surgical resection techniques for locally advanced hilar cholangiocarcinoma.

Authors:  Sanjay Govil; Mettu Srinivas Reddy; Mohamed Rela
Journal:  Langenbecks Arch Surg       Date:  2014-06-04       Impact factor: 3.445

4.  Interleukin-8 is a prognostic indicator in human hilar cholangiocarcinoma.

Authors:  Qi Sun; Fanni Li; Fengkai Sun; Jun Niu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 5.  Resection for Klatskin tumors: technical complexities and results.

Authors:  Ivan Capobianco; Jens Rolinger; Silvio Nadalin
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-18

6.  Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.

Authors:  Hao Li; Zheng-Yun Zhang; Zun-Qiang Zhou; Jiao Guan; Da-Nian Tong; Guang-Wen Zhou
Journal:  Oncotarget       Date:  2016-05-03

7.  Salinomycin inhibits cholangiocarcinoma growth by inhibition of autophagic flux.

Authors:  Johannes Klose; Engin Guerlevik; Tina Trostel; Florian Kühnel; Thomas Schmidt; Martin Schneider; Alexis Ulrich
Journal:  Oncotarget       Date:  2017-12-16

8.  Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?

Authors:  Jun-Ke Wang; Hai-Jie Hu; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Oncotarget       Date:  2017-07-11

9.  Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma.

Authors:  Yongjiang Ba; Ping Yue; Joseph W Leung; Haiping Wang; Yanyan Lin; Bing Bai; Xiaoliang Zhu; Lei Zhang; Kexiang Zhu; Wenhui Wang; Wenbo Meng; Wence Zhou; Ying Liu; Xun Li
Journal:  Endosc Int Open       Date:  2020-01-22

10.  Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.

Authors:  Hai-Jie Hu; Hui Mao; Yong-Qiong Tan; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Springerplus       Date:  2016-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.